Proteomic analysis of human breast cancer

New technologies and clinical applications for biomarker profiling

Bechr Hamrita, Hela Ben Nasr, Karim Chahed, Lotfi Chouchane

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Breast cancer is the most diagnosed cancer in women, accounting for approximately 40,000 deaths annually in the USA. In Tunisia, the incidence of breast cancer is approximately 19 new cases per 100,000 women per year. Significant advances have been made in the areas of detection and treatment, but a significant number of breast cancers are detected late. The enormous progress in proteomics, enabled by recent advances in MS (mass spectrometry), has brought protein analysis back into the limelight of breast cancer research, reviving old areas as well as opening new fields of study like early detection, prognosis, diagnosis, and therapy. Several proteomics technologies have been used to uncover molecular mechanisms associated with breast carcinoma at the global level to discover protein patterns that distinguish disease and disease-free states with high sensitivity and specificity. Breast cancer proteomics has already identified markers of potential clinical interest (such as the molecular chaperone alpha B-crystallin) and technological innovations such as large scale and high throughput analysis are now driving the field. In this review, we discuss the basic features of proteomic technologies, including MS, and we consider the main current applications and challenges of proteomics in breast cancer research, including (i) protein expression profiling of breast tumours, tumour cells, tumour fluids and the auto-immune response of the breast cancer cells. All of these applications continue to benefit from further technological advances, such as the development of proteomics methods, high-resolution, high sensitivity MS, SERPA approach, and advanced bioinformatics for data handling and interpretation.

Original languageEnglish
Pages (from-to)91-98
Number of pages8
JournalJournal of Proteomics and Bioinformatics
Volume3
Issue number3
DOIs
Publication statusPublished - Mar 2010
Externally publishedYes

Fingerprint

Biomarkers
Proteomics
Breast Neoplasms
Technology
Mass spectrometry
Tumors
Proteins
alpha-Crystallin B Chain
Mass Spectrometry
Cells
Molecular Chaperones
Data handling
Bioinformatics
Inventions
Neoplasms
Tunisia
Innovation
Throughput
Computational Biology
Research

Keywords

  • 2-DE
  • Breast markers
  • Mass spectrometry
  • Proteomics
  • SERPA

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology
  • Computer Science Applications

Cite this

Proteomic analysis of human breast cancer : New technologies and clinical applications for biomarker profiling. / Hamrita, Bechr; Nasr, Hela Ben; Chahed, Karim; Chouchane, Lotfi.

In: Journal of Proteomics and Bioinformatics, Vol. 3, No. 3, 03.2010, p. 91-98.

Research output: Contribution to journalArticle

@article{37994aba97754f34a63c1688ffa933c2,
title = "Proteomic analysis of human breast cancer: New technologies and clinical applications for biomarker profiling",
abstract = "Breast cancer is the most diagnosed cancer in women, accounting for approximately 40,000 deaths annually in the USA. In Tunisia, the incidence of breast cancer is approximately 19 new cases per 100,000 women per year. Significant advances have been made in the areas of detection and treatment, but a significant number of breast cancers are detected late. The enormous progress in proteomics, enabled by recent advances in MS (mass spectrometry), has brought protein analysis back into the limelight of breast cancer research, reviving old areas as well as opening new fields of study like early detection, prognosis, diagnosis, and therapy. Several proteomics technologies have been used to uncover molecular mechanisms associated with breast carcinoma at the global level to discover protein patterns that distinguish disease and disease-free states with high sensitivity and specificity. Breast cancer proteomics has already identified markers of potential clinical interest (such as the molecular chaperone alpha B-crystallin) and technological innovations such as large scale and high throughput analysis are now driving the field. In this review, we discuss the basic features of proteomic technologies, including MS, and we consider the main current applications and challenges of proteomics in breast cancer research, including (i) protein expression profiling of breast tumours, tumour cells, tumour fluids and the auto-immune response of the breast cancer cells. All of these applications continue to benefit from further technological advances, such as the development of proteomics methods, high-resolution, high sensitivity MS, SERPA approach, and advanced bioinformatics for data handling and interpretation.",
keywords = "2-DE, Breast markers, Mass spectrometry, Proteomics, SERPA",
author = "Bechr Hamrita and Nasr, {Hela Ben} and Karim Chahed and Lotfi Chouchane",
year = "2010",
month = "3",
doi = "10.4172/jpb.1000126",
language = "English",
volume = "3",
pages = "91--98",
journal = "Journal of Proteomics and Bioinformatics",
issn = "0974-276X",
publisher = "Omics Publishing Group",
number = "3",

}

TY - JOUR

T1 - Proteomic analysis of human breast cancer

T2 - New technologies and clinical applications for biomarker profiling

AU - Hamrita, Bechr

AU - Nasr, Hela Ben

AU - Chahed, Karim

AU - Chouchane, Lotfi

PY - 2010/3

Y1 - 2010/3

N2 - Breast cancer is the most diagnosed cancer in women, accounting for approximately 40,000 deaths annually in the USA. In Tunisia, the incidence of breast cancer is approximately 19 new cases per 100,000 women per year. Significant advances have been made in the areas of detection and treatment, but a significant number of breast cancers are detected late. The enormous progress in proteomics, enabled by recent advances in MS (mass spectrometry), has brought protein analysis back into the limelight of breast cancer research, reviving old areas as well as opening new fields of study like early detection, prognosis, diagnosis, and therapy. Several proteomics technologies have been used to uncover molecular mechanisms associated with breast carcinoma at the global level to discover protein patterns that distinguish disease and disease-free states with high sensitivity and specificity. Breast cancer proteomics has already identified markers of potential clinical interest (such as the molecular chaperone alpha B-crystallin) and technological innovations such as large scale and high throughput analysis are now driving the field. In this review, we discuss the basic features of proteomic technologies, including MS, and we consider the main current applications and challenges of proteomics in breast cancer research, including (i) protein expression profiling of breast tumours, tumour cells, tumour fluids and the auto-immune response of the breast cancer cells. All of these applications continue to benefit from further technological advances, such as the development of proteomics methods, high-resolution, high sensitivity MS, SERPA approach, and advanced bioinformatics for data handling and interpretation.

AB - Breast cancer is the most diagnosed cancer in women, accounting for approximately 40,000 deaths annually in the USA. In Tunisia, the incidence of breast cancer is approximately 19 new cases per 100,000 women per year. Significant advances have been made in the areas of detection and treatment, but a significant number of breast cancers are detected late. The enormous progress in proteomics, enabled by recent advances in MS (mass spectrometry), has brought protein analysis back into the limelight of breast cancer research, reviving old areas as well as opening new fields of study like early detection, prognosis, diagnosis, and therapy. Several proteomics technologies have been used to uncover molecular mechanisms associated with breast carcinoma at the global level to discover protein patterns that distinguish disease and disease-free states with high sensitivity and specificity. Breast cancer proteomics has already identified markers of potential clinical interest (such as the molecular chaperone alpha B-crystallin) and technological innovations such as large scale and high throughput analysis are now driving the field. In this review, we discuss the basic features of proteomic technologies, including MS, and we consider the main current applications and challenges of proteomics in breast cancer research, including (i) protein expression profiling of breast tumours, tumour cells, tumour fluids and the auto-immune response of the breast cancer cells. All of these applications continue to benefit from further technological advances, such as the development of proteomics methods, high-resolution, high sensitivity MS, SERPA approach, and advanced bioinformatics for data handling and interpretation.

KW - 2-DE

KW - Breast markers

KW - Mass spectrometry

KW - Proteomics

KW - SERPA

UR - http://www.scopus.com/inward/record.url?scp=77950139762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950139762&partnerID=8YFLogxK

U2 - 10.4172/jpb.1000126

DO - 10.4172/jpb.1000126

M3 - Article

VL - 3

SP - 91

EP - 98

JO - Journal of Proteomics and Bioinformatics

JF - Journal of Proteomics and Bioinformatics

SN - 0974-276X

IS - 3

ER -